Mycophenolate Mofetil
* Please be kindly noted products are not for therapeutic use. We do not sell to patients.
| Category | Enzyme inhibitors |
| Catalog number | BBF-03983 |
| CAS | 128794-94-5 |
| Molecular Weight | 433.49 |
| Molecular Formula | C23H31NO7 |
| Purity | >98% |
Online Inquiry
Description
Mycophenolate Mofetil is a non-competitive, selective and reversible inhibitor of inosine monophosphate dehydrogenase I/II with IC50 of 39 nM and 27 nM, respectively.
Specification
| Related CAS | 116680-01-4 (hydrochloride) |
| Synonyms | TM-MMF; Myfenax; Mycophenolic acid morpholinoethyl ester; Mycophenolatemofetil; (E)-2-Morpholinoethyl 6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydroisobenzofuran-5-yl)-4-methylhex-4-enoate |
| Storage | Store at -20°C |
| IUPAC Name | 2-morpholin-4-ylethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1H-2-benzofuran-5-yl)-4-methylhex-4-enoate |
| Canonical SMILES | CC1=C(C(=C(C2=C1COC2=O)O)CC=C(C)CCC(=O)OCCN3CCOCC3)OC |
| InChI | InChI=1S/C23H31NO7/c1-15(5-7-19(25)30-13-10-24-8-11-29-12-9-24)4-6-17-21(26)20-18(14-31-23(20)27)16(2)22(17)28-3/h4,26H,5-14H2,1-3H3/b15-4+ |
| InChI Key | RTGDFNSFWBGLEC-SYZQJQIISA-N |
| Source | synthetic |
Properties
| Appearance | White Solid |
| Application | Anti-inflammatory agents, Non-steroidal, Antineoplastic agents, Dermatologic agents, Enzyme inhibitors, Immunosuppressive agents |
| Boiling Point | 637.6±55.0°C (Predicted) |
| Melting Point | 94-95°C |
| Density | 1.222±0.06 g/cm3 (Predicted) |
| Solubility | Soluble in Methanol, Ethanol, Acetone |
Reference Reading
1.Nocturnal Arousal in a 68-Year-Old Woman.
Hoque R, DelRosso LM. J Clin Sleep Med. 2016 Mar 21. pii: jc-00024-16. [Epub ahead of print]
ABSTRACT: The patient is a 68-year-old white woman, with past medical history of autoimmune hepatitis, hypertension, coronary artery disease, depression, and mild cognitive impairment. Medications include: mycophenolate mofetil, lisinopril, aspirin, sertraline, trazadone, and galantamine. She presents for evaluation of witnessed snoring and sleep maintenance insomnia, with frequent tossing and turning during the night. She goes to bed at 9:30 PM and falls asleep within minutes. She has two nocturnal awakenings, usually to urinate. She falls asleep quickly upon returning from the bathroom. She rises at 6 AM, and feels refreshed upon awakening. She denies lower extremity restlessness, or leg kicking during sleep. She has been told she snores, but denies witnessed apnea. She denies use of tobacco, alcohol, or illicit drugs.
2.Pharmacokinetic Variability of Mycophenolic Acid in Pediatric and Adult Patients with Hematopoietic Stem Cell Transplantation.
Zhang D1, Renbarger JL2, Chow DS1. J Clin Pharmacol. 2016 Apr 6. doi: 10.1002/jcph.745. [Epub ahead of print]
The aim of this study was to evaluate the pharmacokinetic variations of mycophenolic acid (MPA), the active metabolite of mycophenolate mofetil (MMF), in both pediatric and adult patients following hematopoietic stem cell transplantation (HSCT). Twenty pediatric patients with a median age of 3 years (range, 0.2-12 years) and thirteen adult patients with a median age of 54 years (range, 18-63 years) were enrolled. Blood samples were collected on days 0, 7, 14, 21 and 30 after allogeneic HSCT. Total and free (unbound) MPA, as well as MPAG were quantified using a validated LC-MS/MS assay. The plasma protein binding of MPA and MPAG did not change significantly in pediatric patients over the one month sampling period post HSCT. However, it increased in adult patients from day 7 to day 30 post HSCT, from 97.3±0.8% to 98.3±0.6% for MPA (P <0.05), and 74.6±9.4% to 82.9±8.1% for MPAG (P <0.05). The plasma protein binding of MPA was significantly higher in males compared to females in both pediatric (98.
3.Everolimus versus mycophenolate mofetil de novo after lung transplantation - a prospective, randomized, open-label trial.
Strueber M1, Warnecke G2,3, Fuge J4, Simon AR5, Zhang R2, Welte T3,4, Haverich A2,3, Gottlieb J3,4. Am J Transplant. 2016 Apr 22. doi: 10.1111/ajt.13835. [Epub ahead of print]
The role of mTOR inhibitors in de novo immunosuppression after lung transplantation is not well-defined. We compared Everolimus versus mycophenolate mofetil in an investigator-initiated single center trial in Hannover, Germany. A total of 190 patients were randomly assigned 1:1 on day 28 post-transplantation to MMF or Everolimus combined with CsA and Steroids. Patients were followed up for two years. Primary endpoint was freedom from BOS. Secondary endpoints were incidence of acute rejections, infections, treatment failure and kidney function. BOS-free survival in ITT analysis was similar in both groups (p=0.174). The study protocol was completed by 51% of enrolled patients. The per-protocol analysis shows incidence of BOS- 1/43 in the everolimus and 8/54 in the MMF group (p=0.041). Less biopsy-proven AR (p=0.005), CMV antigenemia (p=0.005), lower respiratory tract infection (p=0.003) and no leucopenia were seen in the everolimus group. GFR decreased in both groups about 50% within 6 months.
4.Enhancement of Mycophenolate Mofetil Permeation for Topical Use by Eucalyptol and N-Methyl-2-pyrrolidone.
Amnuaikit T1, Songkram C2, Pinsuwan S1. Scientifica (Cairo). 2016;2016:9672718. doi: 10.1155/2016/9672718. Epub 2016 Mar 16.
Mycophenolate mofetil (MMF) is a prodrug of mycophenolic acid (MPA) which can be metabolized by esterase. MMF has been approved by the United States Food and Drug Administration (USFDA) for treatment of psoriasis patient with skin symptoms. However, it remains unclear whether MMF is efficiently effective to treat skin symptoms developed from psoriasis. The insufficient amount of MMF penetrating through the skin results in the treatment failure due to the difficulty in MMF penetration through the stratum corneum. Skin permeation enhancers such as eucalyptol (EUL) and N-methyl-2-pyrrolidone (NMP) potentially aid in increasing skin penetration. This study aimed to investigate the effects of a concentration ratio (% w/v) between two enhancers (EUL and NMP). The results showed that EUL enhanced MMF permeation with an enhancement ratio (ER) of 3.44 while NMP was not able to promote the penetration of MMF. Interestingly, the synergistic effect of the two enhancers was observed with a suitable ratio given that the ER was 8.
Recommended Products
| BBF-02642 | Lactonamycin | Inquiry |
| BBF-01826 | Deoxymannojirimycin | Inquiry |
| BBF-01825 | Loganin | Inquiry |
| BBF-00764 | Cerebroside C | Inquiry |
| BBF-00677 | 3-Amino-3-deoxy-D-glucose | Inquiry |
| BBF-01829 | Deoxynojirimycin | Inquiry |
Bio Calculators
* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C1V1 = C2V2
* Total Molecular Weight:
g/mol
Tip: Chemical formula is case sensitive. C22H30N4O √ c22h30n40 ╳
